Best Stock on the Market

Call Options on NLNK on 10/2/2017

Bullish Flag with 50-day MA.NewLink Genetics Corporation (NLNK) focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer.

Its portfolio includes biologic product candidates based on its HyperAcute cellular immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-2, 3-dioxygenase pathway and the tryptophan-2, 3-dioxygenase pathway.

The company is developing IDO pathway inhibitors comprising indoximod that is in multiple Phase I and Phase II clinical trials for patients with melanoma, pancreatic cancer, malignant brain tumors, metastatic breast cancer, acute myeloid leukemia, prostate cancer, and non-small cell lung cancer (NSCLC); and GDC-0919 and atezolizumab (MPDL3280A) that is in Phase Ib clinical trials for patients with locally advanced or metastatic solid tumors. Its clinical development products include NLG2101 for metastatic breast cancer; NLG2102 for refractory malignant brain tumors; NLG2103 for advanced melanoma; NLG2104 for metastatic pancreatic cancer; NLG2105 for pediatric patients with refractory malignant brain tumors; and NLG2106 for acute myelogenous leukemia.

The company's HyperAcute cellular immunotherapy product candidates under clinical development include tergenpumatucel-L, is being investigated in Phase Ib/II clinical trial for patients with advanced NSCLC; and dorgenmeltucel-L, is being investigated in a Phase II clinical trial for patients with advanced melanoma. Its infectious disease program includes replication-competent recombinant vesicular stomatitis virus, a vaccine technology to treat Ebola and Marburg viruses.

Shares have formed a bullish "flag" and higher share prices are expected for this stock. On September 7th, NLNK shares jumped 45% after firm reported data from its ongoing phase 2 trial of IDO-inhibitor indoximod in advanced melanoma. NewLink Genetics thinks that combining indoximod with PD-1 drugs can deliver even better outcomes for patients because IDO-inhibitors prevent cancer cells from hijacking proteins that suppress immune system responses, and PD-1 drugs improve the ability of T-cells to spot and destroy cancer cells. 

On September 27th, the company entered into a clinical collaboration agreement with AstraZeneca (AZN) to evaluate the combination of indoximod, NewLink Genetics’ small molecule IDO pathway inhibitor, and durvalumab, AstraZeneca’s anti-PD-L1 monoclonal antibody, along with standard of care chemotherapy for patients with metastatic pancreatic cancer.

Higher share prices are expected for this stock.

 

52-Weeks Trading Range: $5.90 - $25.17

Last Trade: $10.18

Trade

  • Buy 1 October $10.00 Call at $0.90
  • For a net debit of $0.90

Profit/Loss Analysis

  • Breakeven at $10.90
  • Maximum profit is unbounded
  • Maximum loss is ($90.00) at strike of $10.00

Closing Summary

  • Sold 1 October $10.00 Call at $2.25

Position closed on 10/4/2017 at price of $2.25 with a 150.00% gain in 2 days.

Updates

10/4/2017 10:00:22 AM

NLNK $10 Calls sold for $2.25

Back to Portfolio